|Bid||45.22 x 1000|
|Ask||45.23 x 800|
|Day's Range||44.86 - 45.30|
|52 Week Range||37.43 - 46.25|
|Beta (3Y Monthly)||0.56|
|PE Ratio (TTM)||28.06|
|Forward Dividend & Yield||1.86 (4.08%)|
|1y Target Est||48.67|
PARIS and TARRYTOWN, N.Y., Nov. 11, 2018 /PRNewswire/ -- New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association (AHA) Scientific Sessions 2018. Praluent® (alirocumab) Injection was associated with fewer deaths from any cause among patients who had previously experienced a heart attack or unstable angina (known as acute coronary syndrome, or ACS), and this was enhanced in patients who were followed for at least 3 years and those who had an LDL-C (low-density lipoprotein cholesterol) of 100 mg/dL or higher at baseline. Some of these deaths could potentially be prevented, particularly among patients who have already been identified as high risk because they have a history of acute coronary syndrome," said Gregory G. Schwartz, M.D., Ph.D., University of Colorado School of Medicine, Aurora, CO, and co-chair of the trial.
Despite massive gains for the Democrats in the midterm elections in the House of Representatives and on the state level, the Republicans managed to hold onto the Senate. This is good for big pharmaceutical stocks (if bad for pharmaceutical users). Had the Democrats won both the House and Senate, scrutiny over drug pricing and the actions of the largest pharmaceutical companies would have resumed.
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
Regeneron Pharmaceuticals crushed Wall Street's third-quarter profit views by 66 cents, though sales of eye drug Eylea lagged outside the U.S.
In the third quarter, Mylan (MYL) reported net sales of $1.04 billion from the European market, which is a flat performance on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the company has witnessed strong demand for branded generics and over-the-counter products in the European market. According to Mylan’s investor presentation, the company has a presence in 35 countries and offers more than 1,500 products in the European market. Mylan is already a leader in terms of value and volume in France and Italy’s generic drug markets.
PARIS and TARRYTOWN, N.Y., Nov. 7, 2018 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published positive detailed results of the 18,924-patient ODYSSEY OUTCOMES trial. The trial met its primary endpoint, showing that Praluent® (alirocumab) Injection significantly reduced the risk of major adverse cardiovascular events (MACE) in patients who had suffered an acute coronary syndrome (ACS), which included a heart attack or unstable angina.
Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.
Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.
In the third quarter, Teva Pharmaceutical’s (TEVA) European revenue fell ~12% YoY (year-over-year) to $1.2 billion from $1.38 billion. Its net European revenue fell YoY to $3.98 billion in the first nine months of this year from $4.02 billion.
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
PARIS and TARRYTOWN, N.Y., Nov. 6, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with moderate-to-severe atopic dermatitis. The target action date for the FDA decision is March 11, 2019.
The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi (SASY.PA) and Regeneron (REGN.O), the companies said on Tuesday. Dupixent was launched in the United States in April 2017 for the treatment of moderate-to-severe eczema in adults, and the product is seen as a key sales driver for both companies.
The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday. Dupixent was launched in the United States in April 2017 for the treatment of moderate-to-severe eczema in adults, and the product is seen as a key sales driver for both companies.
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.
BRIDGEWATER, N.J., Nov. 1, 2018 /PRNewswire/ -- Sanofi has expanded its access program for people living with diabetes to include all Sanofi insulins*, helping patients get the insulin they need at a significantly reduced price. Sanofi's Insulins VALyou Savings Program debuted earlier this year, offering qualifying patients the opportunity to obtain two of Sanofi's insulins at a set price. Beginning today, the program will now include all Sanofi insulins.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Merck & Co., Inc. (NYSE: MRK )(announced FDA approval ...
Disappointing results from Credit Suisse and Royal Dutch Shell set a slightly negative tone in European markets on another busy day of corporate news.
Sanofi and Denali Therapeutics have entered a collaboration agreement valued at up to $1.02 billion to develop molecules to treat neurological and systemic inflammatory diseases.
Sanofi (SNY) beats on earnings as well as sales in the third quarter of 2018. Sales benefit from the performance of Specialty care segment and recovery in Vaccine segment.
PARIS , Oct. 31, 2018 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2018 Change Change at CER 9M 2018 Change Change at CER IFRS net sales reported €9,392m +3.7% +6.3% €25,466m -3.5% +2.1% IFRS net ...
European shares rallied on Wednesday as a tumultuous October drew to a close and strong results from L’Oreal, Sanofi and banks Standard Chartered and Santander soothed investors’ nerves. Laura Frykberg reports.